Integra LifeSciences completes acquisition of Acclarent 

Integra LifeSciences Holdings Corp., a Princeton-based medical technology company, successfully completed its acquisition of Acclarent Inc., according to a Monday announcement.

The addition of Acclarent, a subsidiary of Johnson & Johnson based in Irvine, California, expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel.

The acquisition adds $1 billion to the total addressable market of the company’s offerings, while providing unique market opportunities for access to the attractive ear, nose and throat device segment.

“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, enabling us to deliver transformative technologies to restore patients’ lives,” Mike McBreen, executive vice president and president, Codman Specialty Surgical division, said. “We are looking forward to working alongside our Acclarent colleagues to make a profound impact on ENT and neurosurgery care.”